<DOC>
	<DOC>NCT02004717</DOC>
	<brief_summary>This is an open-label, sequential dose escalation and expansion study to evaluate the safety, tolerability, and pharmacokinetics of DS-8895a in Japanese subjects with advanced solid tumors.</brief_summary>
	<brief_title>Phase 1 Study of DS-8895a in Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Advanced solid tumor that is refractory to standard treatment, or for which no standard treatment is available. Eastern Cooperative Oncology Group performance status(PS) of 0 or 1 Have any of the following concomitant disease or had the history of having following disease within 6 months before enrollment: Cardiac failure (NYHA â‰¥ ClassIII), myocardial infarction, cerebral infarction, unstable angina, arrhythmia requiring treatment, coronaryartery/peripheral artery bypass surgery, cerebrovascular disease, pulmonary thromboembolism, deepvein thrombosis or clinically severe thromboembolic event, or clinically severe pulmonary disease (eg, interstitial pneumonia, pulmonary fibrosis, radiation pneumonia, drug induced pneumonia) Severe or uncontrolled concomitant disease. Clinically active brain metastases defined as symptomatic or requiring treatment.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>advanced solid tumor</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Oncology</keyword>
</DOC>